863 related articles for article (PubMed ID: 22157079)
21. Heterogeneity in MYC-induced mammary tumors contributes to escape from oncogene dependence.
Leung JY; Andrechek ER; Cardiff RD; Nevins JR
Oncogene; 2012 May; 31(20):2545-54. PubMed ID: 21996730
[TBL] [Abstract][Full Text] [Related]
22. Molecular characterizations of Nop16 in murine mammary tumors with varying levels of c-Myc.
Kundel DW; Stromquist E; Greene AL; Zhdankin O; Regal RR; Rose-Hellekant TA
Transgenic Res; 2012 Apr; 21(2):393-406. PubMed ID: 21863248
[TBL] [Abstract][Full Text] [Related]
23. SUMOylation of the transcription factor ZFHX3 at Lys-2806 requires SAE1, UBC9, and PIAS2 and enhances its stability and function in cell proliferation.
Wu R; Fang J; Liu M; A J; Liu J; Chen W; Li J; Ma G; Zhang Z; Zhang B; Fu L; Dong JT
J Biol Chem; 2020 May; 295(19):6741-6753. PubMed ID: 32249212
[TBL] [Abstract][Full Text] [Related]
24. A MYC-Driven Change in Mitochondrial Dynamics Limits YAP/TAZ Function in Mammary Epithelial Cells and Breast Cancer.
von Eyss B; Jaenicke LA; Kortlever RM; Royla N; Wiese KE; Letschert S; McDuffus LA; Sauer M; Rosenwald A; Evan GI; Kempa S; Eilers M
Cancer Cell; 2015 Dec; 28(6):743-757. PubMed ID: 26678338
[TBL] [Abstract][Full Text] [Related]
25. MYC Protein Interactome Profiling Reveals Functionally Distinct Regions that Cooperate to Drive Tumorigenesis.
Kalkat M; Resetca D; Lourenco C; Chan PK; Wei Y; Shiah YJ; Vitkin N; Tong Y; Sunnerhagen M; Done SJ; Boutros PC; Raught B; Penn LZ
Mol Cell; 2018 Dec; 72(5):836-848.e7. PubMed ID: 30415952
[TBL] [Abstract][Full Text] [Related]
26. c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells.
Chen Y; Xu J; Borowicz S; Collins C; Huo D; Olopade OI
BMC Cancer; 2011 Jun; 11():246. PubMed ID: 21668996
[TBL] [Abstract][Full Text] [Related]
27. The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis.
Barsyte-Lovejoy D; Lau SK; Boutros PC; Khosravi F; Jurisica I; Andrulis IL; Tsao MS; Penn LZ
Cancer Res; 2006 May; 66(10):5330-7. PubMed ID: 16707459
[TBL] [Abstract][Full Text] [Related]
28. Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program.
Chen CR; Kang Y; Massagué J
Proc Natl Acad Sci U S A; 2001 Jan; 98(3):992-9. PubMed ID: 11158583
[TBL] [Abstract][Full Text] [Related]
29. SUMOylation of E2F1 Regulates Expression of EZH2.
Du L; Fakih MG; Rosen ST; Chen Y
Cancer Res; 2020 Oct; 80(19):4212-4223. PubMed ID: 32816857
[TBL] [Abstract][Full Text] [Related]
30. Estrogen regulation of vascular endothelial growth factor in breast cancer in vitro and in vivo: the role of estrogen receptor alpha and c-Myc.
Dadiani M; Seger D; Kreizman T; Badikhi D; Margalit R; Eilam R; Degani H
Endocr Relat Cancer; 2009 Sep; 16(3):819-34. PubMed ID: 19398483
[TBL] [Abstract][Full Text] [Related]
31. MYC is a critical target of FBXW7.
Sato M; Rodriguez-Barrueco R; Yu J; Do C; Silva JM; Gautier J
Oncotarget; 2015 Feb; 6(5):3292-305. PubMed ID: 25669969
[TBL] [Abstract][Full Text] [Related]
32. Ecdysoneless Overexpression Drives Mammary Tumorigenesis through Upregulation of C-MYC and Glucose Metabolism.
Mohapatra BC; Mirza S; Bele A; Gurumurthy CB; Raza M; Saleem I; Storck MD; Sarkar A; Kollala SS; Shukla SK; Southekal S; Wagner KU; Qiu F; Lele SM; Alsaleem MA; Rakha EA; Guda C; Singh PK; Cardiff RD; Band H; Band V
Mol Cancer Res; 2022 Sep; 20(9):1391-1404. PubMed ID: 35675041
[TBL] [Abstract][Full Text] [Related]
33. Allosteric Inhibition of Ubiquitin-like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme.
Li YJ; Du L; Wang J; Vega R; Lee TD; Miao Y; Aldana-Masangkay G; Samuels ER; Li B; Ouyang SX; Colayco SA; Bobkova EV; Divlianska DB; Sergienko E; Chung TDY; Fakih M; Chen Y
Cell Chem Biol; 2019 Feb; 26(2):278-288.e6. PubMed ID: 30581133
[TBL] [Abstract][Full Text] [Related]
34. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M
Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511
[TBL] [Abstract][Full Text] [Related]
35. Loss of Fbxw7 triggers mammary tumorigenesis associated with E2F/c-Myc activation and Trp53 mutation.
Meyer AE; Furumo Q; Stelloh C; Minella AC; Rao S
Neoplasia; 2020 Nov; 22(11):644-658. PubMed ID: 33070870
[TBL] [Abstract][Full Text] [Related]
36. MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state.
Poli V; Fagnocchi L; Fasciani A; Cherubini A; Mazzoleni S; Ferrillo S; Miluzio A; Gaudioso G; Vaira V; Turdo A; Gaggianesi M; Chinnici A; Lipari E; Bicciato S; Bosari S; Todaro M; Zippo A
Nat Commun; 2018 Mar; 9(1):1024. PubMed ID: 29523784
[TBL] [Abstract][Full Text] [Related]
37. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.
Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG
FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782
[TBL] [Abstract][Full Text] [Related]
38. Increased Small Ubiquitin-like Modifier-Activating Enzyme SAE1 Promotes Hepatocellular Carcinoma by Enhancing mTOR SUMOylation.
Chen Y; Peng W; Tao Q; Li S; Wu Z; Zhou Y; Xu Q; Shu Y; Xu Y; Shao M; Chen M; Shi Y
Lab Invest; 2023 Jan; 103(1):100011. PubMed ID: 36748193
[TBL] [Abstract][Full Text] [Related]
39. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Kang J; Sergio CM; Sutherland RL; Musgrove EA
BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
[TBL] [Abstract][Full Text] [Related]
40. Diversification of SUMO-activating enzyme in Arabidopsis: implications in SUMO conjugation.
Castaño-Miquel L; Seguí J; Manrique S; Teixeira I; Carretero-Paulet L; Atencio F; Lois LM
Mol Plant; 2013 Sep; 6(5):1646-60. PubMed ID: 23482370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
